Ipamorelin

Original Ipamorelin by Dragon Pharma

Product Overview

Ipamorelin 5 mg contains Ipamorelin, a synthetic pentapeptide classified as a selective growth hormone secretagogue. Manufactured by Dragon Pharma, each vial contains 5 mg of the peptide for research-oriented use.

Ipamorelin activates the growth hormone secretagogue receptor, also known as the ghrelin receptor or GHS-R1a, and stimulates the pituitary gland to release endogenous growth hormone. Early pharmacology research characterized Ipamorelin as relatively selective for growth hormone release, with substantially less stimulation of adrenocorticotropic hormone and cortisol than several older growth hormone-releasing peptides in experimental models.

Ipamorelin has been evaluated experimentally in healthy volunteers and in clinical research involving postoperative gastrointestinal recovery. It has not become an approved treatment for muscle growth, fat loss, anti-aging, athletic recovery, or routine growth hormone replacement.

Product Class

• Growth hormone secretagogue
• Growth hormone-releasing peptide
• Ghrelin-receptor agonist
• Synthetic research peptide
• Non-androgenic investigational compound

Active Ingredient

• Active substance: Ipamorelin
• Concentration: 5 mg per vial
• Dosage form: Peptide vial
• Manufacturer: Dragon Pharma
• Brand: Ipamorelin

Indications

Clinical Research Context

Ipamorelin has been studied as a pharmacological tool for stimulating pulsatile growth hormone release. Human pharmacokinetic and pharmacodynamic research demonstrated a dose-related growth hormone response after intravenous administration to healthy volunteers.

Clinical development also included Phase II research investigating whether Ipamorelin could accelerate recovery of gastrointestinal function after bowel surgery. These studies did not establish Ipamorelin as an approved general-purpose peptide therapy.

Performance and Wellness Context

Within bodybuilding, fitness, and peptide communities, Ipamorelin is commonly discussed in relation to:

• Exercise recovery
• Sleep and nighttime growth hormone secretion
• Lean-mass maintenance
• Body-composition programs
• Connective-tissue recovery
• Healthy-aging and wellness protocols

These uses are not approved medical indications. Evidence supporting meaningful improvements in muscle growth, fat loss, sleep quality, injury healing, or longevity remains limited, particularly for commercially supplied research products.

Mechanism of Action

Ipamorelin binds to the growth hormone secretagogue receptor GHS-R1a. Activation of this receptor stimulates signaling within the hypothalamic-pituitary axis and promotes a pulse of growth hormone release from the anterior pituitary.

Growth hormone can subsequently influence hepatic and peripheral production of insulin-like growth factor 1, commonly abbreviated as IGF-1. The GH–IGF-1 axis contributes to:

• Protein and amino-acid metabolism
• Lipid mobilization
• Glucose regulation
• Bone turnover
• Connective-tissue remodeling
• Cellular growth and recovery pathways

Ipamorelin does not directly provide recombinant growth hormone. It also does not bind to androgen receptors, replace testosterone, or function as an anabolic steroid.

Pharmacokinetics

Ipamorelin produces a relatively short-lived exposure followed by a measurable growth hormone response. In a human dose-escalation study, researchers evaluated both circulating Ipamorelin concentrations and the resulting growth hormone secretion in healthy male volunteers.

• Peptide type: Synthetic pentapeptide
• Primary receptor: GHS-R1a
• Primary pharmacodynamic effect: Pulsatile endogenous GH release
• Administration studied clinically: Parenteral administration
• Clinical status: Investigational

Product-specific absorption, purity, sterility, and biological activity cannot be inferred solely from the label of a non-approved commercial peptide.

Potential Benefits

Potential applications discussed in research and peptide communities include:

• Stimulation of endogenous growth hormone secretion
• Possible support for recovery following exercise
• Potential influence on IGF-1 signaling
• Possible support for lean-tissue maintenance
• Interest in sleep-associated GH pulses
• Research into tissue and metabolic recovery

These proposed benefits should be distinguished from proven clinical outcomes. A review of growth hormone secretagogues concluded that the class may have therapeutic potential, but also emphasized the limited number of rigorous, long-term controlled safety and efficacy studies.

Synergy & Stacking

Within peptide research discussions, Ipamorelin is frequently referenced alongside agents that affect complementary parts of the growth hormone axis.

• CJC-1295 without DAC: Often discussed as a growth hormone-releasing hormone analogue that may complement GHS-R signaling.
• CJC-1295 with DAC: Associated with longer-duration growth hormone-releasing hormone activity.
• Sermorelin: Another GHRH-related peptide discussed for pituitary GH stimulation.
• Tesamorelin: A GHRH analogue with established medical use for a specific indication, but not interchangeable with Ipamorelin.
• BPC-157 or TB-500: Frequently mentioned in experimental recovery combinations, although reliable human evidence for these stacks is lacking.
• GHK-Cu: Commonly discussed in skin and tissue-repair peptide programs.

Combining investigational peptides does not guarantee greater effectiveness. It may complicate glucose regulation, fluid balance, IGF-1 interpretation, product attribution, and adverse-effect monitoring. No standardized or approved Ipamorelin stacking protocol exists.

HRT/TRT Application

Ipamorelin is not a testosterone replacement therapy medication. It does not replace testosterone, increase luteinizing hormone, restore spermatogenesis, or prevent the endocrine suppression caused by anabolic steroids.

Ipamorelin is also not an approved substitute for medically prescribed recombinant growth hormone. Suspected growth hormone deficiency requires specialist endocrine testing because random GH measurements are difficult to interpret and formal stimulation testing may be necessary.

Individuals receiving TRT should not assume that adding Ipamorelin will improve testosterone effectiveness, fertility, body composition, or recovery. Any evaluation of the GH–IGF-1 axis should be based on symptoms, medical history, glucose status, IGF-1 testing, and specialist assessment.

Dosing and Use

Ipamorelin is an investigational peptide, and there is no universally accepted or regulator-approved dosing schedule for bodybuilding, anti-aging, fat loss, sleep improvement, or general wellness.

Published human research used controlled clinical protocols with defined routes of administration, dose escalation, participant screening, and medical observation. Those experimental methods should not be converted directly into self-treatment instructions for a commercially supplied 5 mg vial.

Any medically supervised research use should be individualized according to:

• The specific research objective
• Age and body composition
• Baseline IGF-1 and glucose status
• Cardiovascular and endocrine history
• Concurrent medicines and peptides
• Response to treatment and follow-up laboratory findings

Reconstitution volume, final concentration, administration route, injection frequency, and treatment duration must follow a validated protocol established by a qualified professional. Users should not estimate injection volume without confirming the amount of peptide in the vial, the volume and type of diluent, and the resulting concentration.

Peptide products should never be used when the vial is damaged, unlabeled, expired, visibly contaminated, or supplied without credible sterility and identity documentation.

Female Use

Ipamorelin is not androgenic and is not expected to cause the virilizing effects associated with testosterone or anabolic steroids. However, this does not establish safety in women.

Long-term reproductive data are limited. Use should be avoided during pregnancy, while attempting conception, and during breastfeeding unless part of an authorized clinical study. Women with polycystic ovary syndrome, impaired glucose tolerance, active malignancy, pituitary disease, or unexplained endocrine symptoms require medical assessment before considering any GH-axis compound.

Pre-Cycle Requirements

A medically responsible baseline assessment may include:

• Medical and medication history
• IGF-1 measurement
• Fasting blood glucose
• HbA1c
• Complete blood count
• Liver function tests
• Kidney function tests
• Blood pressure measurement
• Thyroid function tests when indicated
• Evaluation for sleep apnea
• Review of cancer history or unexplained masses

Growth hormone signaling can influence glucose metabolism, tissue growth, fluid balance, and symptoms of sleep-disordered breathing. Baseline evaluation helps determine whether additional endocrine investigation is appropriate.

Comparative Analysis

Ipamorelin vs Hexarelin

• Ipamorelin: Characterized in early research as relatively selective for GH release.
• Hexarelin: Generally regarded as a more potent GHS-R agonist but may produce broader endocrine effects.

Ipamorelin vs GHRP-2

• Ipamorelin: Commonly selected in research for receptor selectivity.
• GHRP-2: Potent GH secretagogue associated with appetite and broader ghrelin-related effects.

Ipamorelin vs GHRP-6

• Ipamorelin: Often associated with less pronounced hunger.
• GHRP-6: More commonly linked to appetite stimulation through ghrelin-receptor activity.

Ipamorelin vs CJC-1295

• Ipamorelin: Activates the growth hormone secretagogue receptor.
• CJC-1295: Acts through the growth hormone-releasing hormone receptor.

Ipamorelin vs Recombinant HGH

• Ipamorelin: Stimulates endogenous pituitary GH pulses.
• Recombinant HGH: Directly supplies exogenous growth hormone.

Ipamorelin vs MK-677

• Ipamorelin: Injectable peptide with relatively short exposure.
• MK-677: Orally active, longer-acting non-peptide growth hormone secretagogue.

Conclusion

Ipamorelin 5 mg is a synthetic growth hormone secretagogue that activates GHS-R1a and stimulates pulsatile endogenous GH release. Early research identified Ipamorelin as comparatively selective for growth hormone secretion, and human studies confirmed measurable pharmacodynamic activity.

Despite widespread discussion in recovery, body-composition, and healthy-aging communities, Ipamorelin remains investigational. It is not approved as a bodybuilding peptide, TRT adjunct, anti-aging therapy, or substitute for prescribed growth hormone. Product quality, endocrine monitoring, glucose status, sports eligibility, and the absence of robust long-term clinical data are important considerations when evaluating this peptide.